Table 4.
Univariable and multivariable analysis of effects of clinicopathological variables on DFS
| Variables | nCT | nCRT | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | Univariable analysis | Multivariable analysis | n | Univariable analysis | Multivariable analysis | |||||
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |||
| Age | 298 | 1.00 (0.98–1.02) | 0.91 | 391 | 1.01 (1.00–1.03) | 0.11 | ||||
| Sex | ||||||||||
| Male | 265 | Reference | 352 | Reference | ||||||
| Female | 33 | 0.92 (0.59–1.46) | 0.73 | 39 | 0.74 (0.46–1.20) | 0.22 | ||||
| Tumor location | ||||||||||
| Upper/middle esophagus | 11 | Reference | 25 | Reference | ||||||
| Lower | 150 | 0.90 (0.44–1.84) | 0.76 | 229 | 1.00 (0.59–1.68) | 0.99 | ||||
| GO junction | 137 | 0.86 (0.42–.78) | 0.69 | 137 | 0.90 (0.52–1.56) | 0.71 | ||||
| ypT stage | ||||||||||
| T0 | 14 | Reference | Reference | 56 | Reference | Reference | ||||
| T1 | 46 | 0.74 (0.30–1.83) | 0.51 | 0.66 (0.26–1.65) | 0.37 | 74 | 1.74 (0.98–3.09) | 0.06 | 1.77 (0.98–3.20) | 0.06 |
| T2 | 46 | 0.85 (0.34–2.10) | 0.72 | 0.57 (0.22–1.65) | 0.23 | 77 | 1.97 (1.12–3.45) | 0.02 | 1.52 (0.83–2.77) | 0.18 |
| T3 | 177 | 1.73 (0.76–3.95) | 0.19 | 0.60 (0.25–1.44) | 0.25 | 176 | 3.00 (1.80–5.00) | < 0.001 | 2.15 (1.19–3.90) | 0.01 |
| T4 | 15 | 3.52 (1.33–9.32) | 0.01 | 1.12 (0.395–3.18) | 0.83 | 5 | 6.36 (2.13–19.05) | 0.001 | 4.19 (1.19–14.68) | 0.03 |
| ypN stage | ||||||||||
| N0 | 94 | Reference | Reference | 212 | Reference | Reference | ||||
| N1 | 95 | 2.85 (1.90–4.30) | < 0.001 | 2.59 (1.70–3.95) | < 0.001 | 120 | 2.40 (1.77–3.26) | < 0.001 | 2.36 (1.69–3.31) | < 0.001 |
| N2 | 62 | 4.71 (3.06–7.26) | < 0.001 | 4.98 (3.11–8.00) | < 0.001 | 41 | 3.13 (2.06–4.76) | < 0.001 | 2.57 (1.61–4.10) | < 0.001 |
| N3 | 47 | 5.88 (3.72–9.29) | < 0.001 | 5.42 (3.29–8.94) | < 0.001 | 27 | 4.35 (2.71–6.99) | < 0.001 | 3.27 (1.92–5.57) | < 0.001 |
| ypM stage | ||||||||||
| M0 | 277 | Reference | Reference | 375 | Reference | Reference | ||||
| M1 | 21 | 5.10 (3.20–8.14) | < 0.001 | 5.48 (3.32–9.04) | < 0.001 | 13 | 4.16 (2.36–7.33) | < 0.001 | 4.30 (2.26–8.18) | < 0.001 |
| Mandard | ||||||||||
| TRG 1–2 | 35 | Reference | 181 | Reference | Reference | |||||
| TRG 3–5 | 232 | 0.61 (0.23–1.65) | 0.33 | 198 | 2.28 (1.34–3.88) | 0.002 | 0.85 (0.60–1.19) | 0.33 | ||
| Resection margin | ||||||||||
| R0 | 247 | Reference | Reference | 360 | Reference | Reference | ||||
| R1/R2 | 61 | 3.01 (2.18–4.14) | < 0.001 | 1.97 (1.38–2.81) | < 0.001 | 31 | 1.73 (1.10–2.72) | 0.02 | 0.96 (0.56–1.63) | 0.87 |
| SRC status | ||||||||||
| Non-SRC | 234 | Reference | Reference | 326 | Reference | Reference | ||||
| SRC | 64 | 1.50 (1.08–2.07) | 0.02 | 1.27 (0.90–1.78) | 0.17 | 65 | 0.98 (0.68–1.41) | 0.92 | 0.76 (0.51–1.12) | 0.17 |
Variables were entered in the multivariable model if the p value was < 0.1 in the univariable analysis
The Mx (n = 2) and Tis (n = 2) categories were not included in the analysis
nCRT neoadjuvant chemoradiotherapy, nCT neoadjuvant chemotherapy, HR hazard ratio, CI confidence interval, GO gastroesophageal, TRG tumor regression grade, SRC signet ring cell, DFS disease-free survival